A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study).

Brief description of study

You can participate in this study if you are diagnosed with Hormone Receptor (HR) positive, HER2 negative breast cancer (Stages I-II). The purpose of this study is to determine the Safety, Tolerability, and Efficacy of the study drug (ribociclib) when administered with other study drugs (fulvestrant, anastrozole, letrozole or exemestane). The study is also being done to learn more about how the study drugs are absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medication during the entire study period.


Clinical Study Identifier: s22-00921
Other Investigators: Yelena Novik, Maryann J Kwa, Theresa Ryan, Jennifer Wu, Marleen I Meyers, Cristian C Papazoglu Statescu, Andrea Popescu-Martinez, Amanda Marie Talmadge, Sylvia Adams, Danielle Seidman, Alexander A Hindenburg, Caitlin Elizabeth Ryan, Anastasiya Apanasyuk, Ruth Oratz, Natalie Jill Klar, Mary Lynn R Nierodzik, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.